JPMorgan Chase & Co. Reiterates “$183.00” Price Target for BioNTech (NASDAQ:BNTX)

JPMorgan Chase & Co. set a $183.00 target price on BioNTech (NASDAQ:BNTXGet Rating) in a report issued on Tuesday morning, Borsen Zeitung reports.

A number of other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of BioNTech from a strong-buy rating to a hold rating in a report on Thursday, January 27th. Jefferies Financial Group set a $230.00 target price on BioNTech in a research report on Monday, May 9th. Deutsche Bank Rese… set a $200.00 price target on BioNTech in a report on Friday, April 1st. UBS Group cut their price objective on BioNTech from $450.00 to $300.00 and set a buy rating for the company in a research report on Tuesday, April 5th. Finally, Canaccord Genuity Group lowered their target price on shares of BioNTech from $450.00 to $300.00 and set a buy rating for the company in a research note on Tuesday, April 5th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, BioNTech has a consensus rating of Hold and a consensus price target of $260.81.

Shares of NASDAQ:BNTX opened at $158.84 on Tuesday. BioNTech has a 52-week low of $121.32 and a 52-week high of $464.00. The stock has a market cap of $39.20 billion, a P/E ratio of 2.76 and a beta of -0.28. The business has a fifty day moving average of $158.62 and a two-hundred day moving average of $203.19. The company has a quick ratio of 4.18, a current ratio of 5.05 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTXGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported $15.98 earnings per share for the quarter, beating the consensus estimate of $9.14 by $6.84. BioNTech had a net margin of 55.13% and a return on equity of 122.24%. The firm had revenue of $6.37 billion for the quarter, compared to analysts’ expectations of $4.50 billion. During the same quarter in the previous year, the company posted $5.29 EPS. The company’s revenue was up 211.2% compared to the same quarter last year. On average, equities analysts anticipate that BioNTech will post 34.49 earnings per share for the current year.

The company also recently declared a — dividend, which will be paid on Friday, June 17th. Investors of record on Friday, June 3rd will be paid a $1.5342 dividend. The ex-dividend date of this dividend is Thursday, June 2nd. This represents a yield of 1.1%.

Several large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its position in shares of BioNTech by 226.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,184 shares of the company’s stock worth $596,000 after purchasing an additional 1,514 shares during the last quarter. Truist Financial Corp lifted its holdings in BioNTech by 45.9% during the 3rd quarter. Truist Financial Corp now owns 3,327 shares of the company’s stock worth $908,000 after buying an additional 1,047 shares during the last quarter. Mackenzie Financial Corp acquired a new position in shares of BioNTech during the 3rd quarter worth about $290,000. Picton Mahoney Asset Management purchased a new position in shares of BioNTech in the 3rd quarter valued at about $164,000. Finally, Allianz Asset Management GmbH raised its position in shares of BioNTech by 69.6% during the 3rd quarter. Allianz Asset Management GmbH now owns 78,188 shares of the company’s stock worth $21,344,000 after acquiring an additional 32,076 shares in the last quarter. 14.42% of the stock is currently owned by institutional investors.

About BioNTech (Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Stories

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.